WHAT IS FEMALE SEXUAL DYSFUNCTION?
Sexual dysfunction is defined as a persistent or recurrent sexual problem that causes marked distress or interpersonal difficulty. The 2013 Diagnostic and Statistical Manual of Mental Disorders classifies female sexual dysfunction (FSD) into three domains: female sexual interest/arousal disorder; female orgasmic disorder; and genito-pelvic pain/penetration disorder. Female sexual interest/arousal disorder occurs when a woman experiences persistent or recurrent inability to attain sexual arousal, or to maintain arousal until the completion of a sexual activity. This disorder can also refer to an inadequate lubrication-swelling response that is normally present during arousal and sexual activity. Female orgasmic disorder occurs when a woman either cannot reach orgasm or has trouble reaching orgasm even after ample sexual stimulation. This disorder can be primary, or secondary due to ageing. Genito-pelvic pain/penetration disorder, commonly known as vaginismus, is diagnosed when a patient experiences persistent or recurrent difficulty with one or more of the following for a minimum duration of six months: (a) vaginal penetration during intercourse; (b) marked vulvovaginal or pelvic pain during vaginal intercourse or penetration attempts; (c) marked fear or anxiety about vulvovaginal or pelvic pain in anticipation of, during, or as a result of vaginal penetration; and (d) marked tensing or tightening of the pelvic floor muscles during attempted vaginal penetration.

The worldwide prevalence of FSD ranges from 27% to 70%. FSD is associated with various demographic characteristics, including age and educational level. Sociocultural barriers, taboos and misconceptions make the estimation of prevalence difficult. The aetiology of FSD is believed to be multifactorial in nature, involving biological, physiological, anatomical, medical, affective, interpersonal, psychological and context-related factors. Chronic illnesses, such as infections, vascular disease, hypothyroidism, diabetes mellitus and neurologic disease, malignancies and medications can directly or indirectly affect sexual function. Therefore, a multidisciplinary evaluation involving trained specialists and psychologists, as well as a holistic treatment approach that addresses all these issues, is important. Assessment of FSD is best approached using a biopsychosocial approach and should include a sexual history and physical examination. Laboratory testing is usually not required to identify the causes. If left untreated, FSD can affect the quality of life, self-esteem and interpersonal relationships of the sufferer.

HOW RELEVANT IS THIS TO MY PRACTICE?
Combined oral contraceptives (COCs) are an affordable and reversible form of contraception. It is the third most popular contraceptive method, after female sterilisation and intrauterine devices, as it provides a high degree of contraceptive efficacy with an excellent safety profile and is a reversible method of birth control that is available throughout the world. The use of COCs worldwide in women of reproductive age was reported to be around 14% in 2015. While there are existing guidelines from the World Health Organization (WHO) and the United States’ Centers for Disease Control and Prevention (CDC) on the use of COCs, they do not mention their effect on sexuality, even though there is evidence to suggest that older-generation COCs can cause female sexual dysfunction.

Starting patients on combined oral contraceptive pills
Prior to starting COCs, the physician should evaluate the patient for contraindications and risks associated with COCs by conducting a thorough history and physical examination (Table 1). After excluding any contraindications, the physician will recommend the method in which COCs should be started based on the patient’s last menstrual period and other associated conditions, such as whether she is starting contraception post-partum or switching from another contraceptive method (Fig. 1).
Important considerations when prescribing COCs to women of reproductive age

It is important to consider the effects of COCs on sexual function when prescribing them to women of reproductive age. WHO and CDC have establishedgood practice guidance on how to assess women before prescribing COCs. However, neither recommends the screening and assessment of sexual function, which we consider to be important. First, physicians should screen patients for pre-existing FSD, and inform them of the possible sexual side effects of COCs before prescribing them. Second, COCs that contain drospirenone and ethinylestradiol or gestodene and ethinylestradiol are preferred choices for women who are concerned about sexual dysfunction, as they are less likely to cause FSD. Third, patients who are taking COCs need regular review; during clinic visits, physicians should inquire about any sexual side effects, such as decreased sexual desire and dyspareunia. Fourth, in adolescents, a non-COC option for treating acne is preferred over COCs; however, if COCs are prescribed to this age group, the treatment duration should not exceed two years.

Recommended follow-up

There is currently no recommended interval for follow-up after the initiation of COCs. However, in view of some of the effects of COCs, we recommend that patients should be followed up at one month, three months and six months after initiation of COCs, and yearly thereafter. During the follow-up visit, the physician should: (a) assess for compliance and pattern of withdrawal bleeding; (b) assess for any adverse reactions to the medications such as headache; (c) assess for sexual function, particularly in the domains of sexual desire and dyspareunia; (d) measure blood pressure; and (e) calculate the body mass index.
TAKE HOME MESSAGES

1. Thorough history-taking and appropriate physical examination are important to assess a patient’s suitability for use of COCs.
2. There is no indication to perform any tests before starting COCs.
3. COCs can cause or worsen FSD in reproductive women.
4. We recommend that clinicians incorporate taking of a sexual history before prescribing COCs and regular assessments of sexual function in patients taking COCs.
5. Women should be encouraged to discuss the sexual and emotional effects of COCs, and have an informed conversation with their healthcare provider.

REFERENCES

1. One must perform a PAP smear before the initiation of COCs.
2. If a woman reports sexual dysfunction after the initiation of COCs, switching over to newer-generation COCs containing drospirenone and ethinylestradiol, or gestodene and ethinylestradiol may improve the symptoms.
3. One must not initiate COCs in a woman > 40 years old, even if she does not have any other risk factors.
4. Treatment of acne in adolescent girls can lead to sexual dysfunction.
5. Serum hormonal profile must be evaluated in any woman with sexual dysfunction.
6. Any women with systolic blood pressure (BP) ≥ 160 mmHg or diastolic BP ≥ 100 mmHg should not be prescribed COCs.
7. COCs can be initiated within three weeks of delivery if the woman requires contraception and is not breastfeeding.
8. For women with no medical history, there is no need for additional barrier contraception if COCs are initiated within five days from the last menstrual period.
9. One should avoid prescribing COCs to women who have diabetic retinopathy.
10. COCs are contraindicated in women with body mass index > 30 kg/m².
11. Sexual history and function should be assessed before and after the initiation of COCs.
12. If baseline BP is normal before initiation of COCs, there is no need for a repeat BP measurement when the patient is on COCs.
13. COCs can cause dyspareunia.
14. Female sexual dysfunction is very rare and occurs in less than 10% of women worldwide.
15. COCs should not be initiated in a woman with a history of venous thromboembolism.
16. In women with migraine associated with aura, one should avoid initiation of COCs.
17. COCs can be used up to the age of menopause if the woman does not have other contraindications.
18. COCs should be avoided in women with a history of ischaemic heart disease or stroke.
19. Before initiation of COCs, one must perform a baseline liver function test.
20. Yearly PAP smear should be performed for a woman on COCs.